Gilead Sciences director Kramer sells 10,376 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Gilead Sciences, Inc. (GILD) director Kelly A. Kramer exercised 10,376 non-qualified stock options on November 12, 2026, at an exercise price of $66.92 per share, acquiring 10,376 common shares. Kramer reported sales of 10,376 common shares that day in four transactions: 1,676 at $168.2255, 3,800 at $169.4423, 4,700 at $170.4941 and 200 at $171.44 per share. The transactions were made under a Rule 10b5-1 trading plan adopted August 13, 2026.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Non-qualified Stock Option (Right to Buy) F1, F5 | 10,376 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 10,376 | $66.92 | $694K |
| Sale | Common Stock F1, F2 | 1,676 | $168.2255 | $282K |
| Sale | Common Stock F1, F3 | 3,800 | $169.4423 | $644K |
| Sale | Common Stock F1, F4 | 4,700 | $170.4941 | $801K |
| Sale | Common Stock F1 | 200 | $171.44 | $34K |
Footnotes (5)
- F1. The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2026.
- F2. Sale prices for the transactions reported range from $167.95 to $168.88. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
- F3. Sale prices for the transactions reported range from $169.04 to $169.90. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
- F4. Sale prices for the transactions reported range from $170.08 to $171.01. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
- F5. 25% of the shares subject to the option vested on each three-month anniversary measured from May 10, 2017 such that 100% of the shares subject to the option were fully vested and exercisable on May 10, 2018.
Key Figures
Key Terms
Rule 10b5-1 trading plan regulatory
Non-qualified Stock Option (Right to Buy) financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many GILD stock options did Kelly A. Kramer exercise, and at what price?
When did the GILD director's stock option expire?
AI-generated analysis. How Rhea-AI works. Not financial advice.